Menu Search
Equities

Bavarian Nordic A/S

BAVA:CPH

Bavarian Nordic A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)246.20
  • Today's Change3.20 / 1.32%
  • Shares traded305.57k
  • 1 Year change+60.13%
  • Beta1.7147
Data delayed at least 15 minutes, as of Sep 19 2024 16:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 13-Sep-24
Select bar for recommendation details.
Recommendations13-Sep-24
Buy3
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in DKK

The 7 analysts offering 12 month price targets for Bavarian Nordic A/S have a median target of 294.00, with a high estimate of 380.00 and a low estimate of 230.00. The median estimate represents a 19.42% increase from the last price of 246.20.
High54.3%380.00
Med19.4%294.00
Low-6.6%230.00

Earnings history & estimates in DKK

On May 08, 2024, losses of -1.50 per share.
The next earnings announcement is expected on Mar 05, 2025.
Average growth rate+39.22%
Bavarian Nordic A/S reported annual 2023 earnings of 19.20 per share on Mar 06, 2024.
Average growth rate+33.78%
More ▼

Revenue history & estimates in DKK

Bavarian Nordic A/S had 2nd quarter 2024 revenues of 1.43bn. This bettered the 1.25bn estimate of the one analyst covering the company. This was 14.01% above the prior year's 2nd quarter results.
Average growth rate+13.78%
Bavarian Nordic A/S had revenues for the full year 2023 of 7.06bn. This was 124.14% above the prior year's results.
Average growth rate+93.06%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.